SRx Health Solutions faces CCAA restructuring after steep revenue drop and liquidity crisis

SRx Health Solutions Inc. (BTTR) (PINK: BTTR) - quick read on what's happening inside the company.

Snapshot - what management did and where the business stands
* April 24, 2025: Reverse merger with SRx Canada; Better Choice renamed SRx Health Solutions and consolidated Canadian pharmacy operations with legacy Halo pet business.
* Post-close financing and corporate activity: $8.8M private placement (Apr 24, 2025); subsequent July 7, 2025 Securities Purchase Agreement for $7.65M of senior secured convertible notes; Equity Line of Credit (up to $50M) put in place (July 7, 2025).
* Aug 12, 2025: SRx Canada (operating subsidiary) filed for creditor protection under Canada's CCAA - material for liquidity and restructuring prospects.

Key points & headline statistics (as presented)
* Three months ended June 30, 2025 - Net sales: $11,447; Cost of goods sold: $8,028; Gross margin: $3,419.
* Nine months ended June 30, 2025 - Net sales: $41,082 vs $117,122 (nine months 2024) - a decline of $76,040 (65%).
* Nine months COGS: $30,786; Gross margin: $10,296.
* SG&A (nine months): $39,783 (up from $31,627).
* Impairment expense recognized: $2,690 (three and nine months ended June 30, 2025).
* Operating loss (three months): $(17,422); (nine months): $(32,177).
* Net loss after taxes (three months): $(15,133); (nine months): $(29,745).
* Net loss per share (basic) - three months: $(0.74); nine months: $(1.54).
* Balance sheet (June 30, 2025): Cash $912; Accounts receivable, net $8,138; Inventories $5,132; Total Assets $33,985.
* Liabilities / capitalization: Total current liabilities $74,108; Total liabilities $79,865; Shareholders' deficit $(45,880); Accumulated deficit $(98,424).
* Cash flow (nine months ended June 30, 2025): Operating activities used $(15,744); Investing provided $13,280 (asset sales, cash acquired in business combination); Financing provided $3,154. Ending cash $912.

Income statement - positives
* Company still generates gross margin: three months gross margin $3,419; nine months $10,296 - shows product/service markup exists when inventory and fulfillment operate.
* Other income and asset sales materially improved results: nine months Other income (net) $3,457 and net gain on asset disposals contributed $4.3M (helps cash and offsets losses temporarily).
* Transaction-generated non-recurring items: bargain purchase gain $1,693 recognized and multiple one-time financing and equity raises ($8.8M private placement) that increased liquidity in the short run.
* Consumer Products (Halo) contribution visible: three months US revenue $2,673 (segment diversification into consumer packaged goods).

Income statement - negatives / red flags
* Large and growing losses: Net loss $(29,745) YTD; operating loss $(32,177) YTD - sustained operating deficits.
* Sharp revenue decline: net sales down 65% YoY for the nine-month comparison ($41,082 vs $117,122) - indicates major disruption in core pharmacy throughput.
* Overhead burden: SG&A of $39,783 for nine months outweighs gross profit of $10,296 - selling/general/admin costs are crushing operating profitability.
* Repeated impairments and write-downs: intangible impairment $2,690 this period; prior goodwill impairment left goodwill at $0 - signals failed expected synergies or lost contracts.
* Cash burn and liquidity stress: operating cash used $(15,744) YTD; cash on hand only $912 at June 30, 2025; working capital deficiency and current liabilities ($74,108) far exceed cash.
* Debt covenant failures: not in compliance with CWB covenants as of June 30, 2025 and Sep 30, 2024 - debt classified as current and callable; active discussions but no assurance of cure.
* Going-concern & restructuring: management discloses substantial doubt about going concern; SRx Canada filed for CCAA protection in August 2025 - court-supervised restructuring underway and outcomes uncertain.
* High non-cash compensation and dilution risk: share-based compensation of $4,451 YTD; numerous share issuances, warrants and convertible instruments outstanding - potential dilution and continued cash-conservation via equity-for-services.

What to watch next (short list)
* CCAA process outcome for SRx Canada - impacts cure of lender defaults, asset sales, DIP financing and ultimate recovery for creditors and shareholders.
* Covenant amendment or refinancing with CWB - failure to restructure debt would likely accelerate defaults.
* Cash runway after July convertible note financing and ELOC availability - will new financings materially stabilize liquidity or add dilutive pressure?
* Revenue recovery in specialty pharmacy dispensing (patient volume and high-cost scripts) - core driver of gross profit and cash flow.
* Any further asset sales or divestitures (management already selling non-core pharmacies) - will they produce sustainable liquidity or only one-time gains?

Bottom line: the company still has revenue-generating operations and some one-time gains and financings that temporarily ease liquidity, but material operating losses, a steep YoY revenue decline, covenant breaches and a subsequent CCAA filing make this a high-risk restructuring story. Investors should treat BTTR as speculative and monitor restructuring outcomes, creditor negotiations, and near-term cash events closely.